- Home
- SRPT
as 05-09-2025 4:00pm EST
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
| Founded: | 1980 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | N/A | IPO Year: | 1997 |
| Target Price: | $131.09 | AVG Volume (30 days): | 4.0M |
| Analyst Decision: | Buy | Number of Analysts: | 23 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.59 | EPS Growth: | N/A |
| 52 Week Low/High: | $35.46 - $173.25 | Next Earning Date: | 05-06-2025 |
| Revenue: | $2,233,371,000 | Revenue Growth: | 59.15% |
| Revenue Growth (this year): | 64.51% | Revenue Growth (next year): | 22.40% |
Stock Insider Trading Activity of Sarepta Therapeutics Inc. (DE) (SRPT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Nicaise Claude | SRPT | Director | Mar 12 '25 | Sell | $99.64 | 2,491 | $248,203.24 | 27,812 |
Latest Sarepta Therapeutics Inc. (DE) News
SRPT Breaking Stock News: Dive into SRPT Ticker-Specific Updates for Smart Investing
Insider Monkey
10 hours ago
Is Sarepta Therapeutics, Inc. (SRPT) The Best Stock That Will Bounce Back?
Business Wire
a day ago
Sarepta Therapeutics to Present at the BofA Securities Health Care Conference
TipRanks
a day ago
Sarepta price target lowered to $125 from $183 at Needham
MT Newswires
a day ago
UBS Cuts Price Target on Sarepta Therapeutics to $85 From $188, Keeps Buy Rating
Simply Wall St.
a day ago
Sarepta Therapeutics First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
Insider Monkey
2 days ago
Why Sarepta Therapeutics, Inc. (SRPT) Nosedived on Wednesday
StockStory
2 days ago
Q1 Earnings Recap: AbbVie (NYSE:ABBV) Tops Therapeutics Stocks
StockStory
2 days ago
Therapeutics Stocks Q1 Results: Benchmarking Sarepta Therapeutics (NASDAQ:SRPT)
Compare SRPT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SRPT Sarepta Therapeutics Inc. (DE) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.